Apararenone

Apararenone is a nonsteroidal antimineralocorticoid which is under development by Mitsubishi [Tanabe Pharma] for the treatment of diabetic nephropathies and non-alcoholic steatohepatitis. It was also previously being developed for the treatment of hypertension, but development was discontinued for this indication. Apararenone acts as a highly selective antagonist of the mineralocorticoid receptor, the receptor for aldosterone. As of 2017, it is in Phases of [clinical research#Phase II|phase II] clinical trials.